指南与共识头颈部肿瘤放疗放疗物理与技术

美国Delphi共识:淋巴结阴性皮肤鳞状细胞癌的辅助放疗

US-based Delphi Consensus Study on Adjuvant Radiation Therapy (ART) in Node-Negative Cutaneous Squamous Cell Carcinoma (CSCC).
指南 / 共识 · Int J Radiat Oncol Biol Phys · 2026-10-16

该Delphi共识研究汇集35名多学科专家,针对淋巴结阴性皮肤鳞状细胞癌(CSCC)术后辅助放疗(ART)的患者与肿瘤选择、时机、剂量等形成推荐。共识推荐在无法进一步手术且切缘阳性时行ART,并明确了高危因素(如局部复发或淋巴结转移5年累积发生率≥20%、骨侵犯、神经侵犯等)及放疗剂量方案,但未对选择性淋巴结照射达成共识。

要点

  • 切缘阳性且无法再手术时推荐ART(35/35,100%)。
  • 推荐ART的高危因素包括5年局部复发或淋巴结转移累积发生率≥20%、骨/神经侵犯等。
  • 放疗科医生一致认为ART最佳窗口为术后4-8周,剂量60-66 Gy/2 Gy或50-55 Gy/2.5 Gy。

核心结论

  • 该Delphi研究为淋巴结阴性高危CSCC术后ART提供了基于专家共识的框架,以标准化治疗并指导未来指南。

研究设计与样本

  • Delphi共识研究, panel包括35名专家:放射肿瘤学15名、皮肤科/Mohs显微手术9名、肿瘤内科7名、头颈外科3名、外科肿瘤学1名;共识定义为≥80%一致,近共识为70-79%一致。

主要发现

  • 当无法进一步手术但肿瘤有阳性大体或组织学/显微镜下切缘时,共识推荐ART(35/35,100%)。
  • 对于切缘阴性手术后推荐对瘤床行ART的共识或近共识因素包括:5年局部复发累积发生率≥20%(29/35,83%)或淋巴结转移≥20%(27/35,77%)、大体皮质骨/骨髓侵犯(32/35,91%)、颅底侵犯(32/35,91%)、4个危险因素(RF)(35/35,100%)、3个RF(30-33/35,86-94%)、PNI≥0.1 mm且合并另一个RF(30/35,86%)、临床神经侵犯(31/35,89%)。
  • 免疫状态影响ART决策(30/35,86%),77%(27/35)更倾向于为免疫抑制患者推荐ART。
  • 共识认为新辅助免疫治疗后病理完全缓解可省略ART(34/35,97%)。
  • 放射肿瘤学家中,100%(15/15)同意ART最佳窗口为4-8周,80%(12/15)认为大分割方案可行;处方剂量共识为60-66 Gy/2 Gy/fx(15/15,100%)或50-55 Gy/2.5 Gy/fx(13/15,87%),且93%(14/15)认为浅表放疗和近距离放疗不适合淋巴结阴性高危CSCC的ART。

关键数值与推荐

  • 推荐ART的切缘状态:阳性大体或组织学/显微镜下切缘且无法进一步手术(35/35,100%)。
  • 推荐ART的复发/转移风险阈值:5年局部复发累积发生率≥20%(29/35,83%)或淋巴结转移≥20%(27/35,77%)。
  • 推荐ART的高危因素:4个RF(35/35,100%)、3个RF(30-33/35,86-94%)、PNI≥0.1 mm且合并另一个RF(30/35,86%)、临床神经侵犯(31/35,89%)、大体皮质骨/骨髓侵犯(32/35,91%)、颅底侵犯(32/35,91%)。
  • ART时机与剂量:最佳窗口4-8周(15/15,100%);处方剂量60-66 Gy/2 Gy/fx(15/15,100%)或50-55 Gy/2.5 Gy/fx(13/15,87%);大分割方案可行(12/15,80%)。
  • 省略ART:新辅助免疫治疗后病理完全缓解(34/35,97%);浅表放疗和近距离放疗不适当(14/15,93%)。

临床怎么用

  • 对于淋巴结阴性高危CSCC术后患者,可依据共识推荐的风险因素(如切缘阳性、多个RF、骨/神经侵犯、高复发/转移风险)决策是否行ART。
  • 放疗科医生应优先在术后4-8周内启动ART,并选择共识支持的剂量方案(60-66 Gy/2 Gy/fx或50-55 Gy/2.5 Gy/fx),避免使用浅表放疗或近距离放疗。
  • 免疫抑制状态和新辅助免疫治疗后病理完全缓解可影响ART决策,前者更倾向推荐ART,后者可考虑省略ART。

局限性

  • 该研究为Delphi共识,基于专家意见而非高级别证据,可能存在实践差异。
  • 未对选择性淋巴结照射达成共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is a paucity of high-level evidence for adjuvant radiation therapy (ART) in cutaneous squamous cell carcinoma (CSCC) creating practice variations. This study provides expert consensus recommendations on patient and tumor selection, timing, duration, dosage, and additional considerations for ART in node-negative CSCC. METHODS: The Delphi panel included 35 experts in radiation oncology (15), dermatology/Mohs micrographic surgery (9), medical oncology (7), head and neck surgery (3), and surgical oncology (1). Consensus was defined as ≥80% concordance; near-consensus 70-79% concordance. RESULTS: Consensus was reached to recommend ART when further surgery is not possible, but the tumor has positive gross or histologic/microscopic margins (35/35, 100%). Key consensus or near-consensus recommendations for recommending ART to the tumor bed following negative-margin surgery include: 5-year cumulative incidence of local recurrence (29/35, 83%) or nodal metastasis (27/35, 77%) ≥ 20%; gross cortical bone/marrow invasion (32/35, 91%); skull base invasion (32/35, 91%); 4 risk factors (RF) (35/35, 100%); 3 RF (30-33/35, 86-94%); PNI ≥ 0.1 mm and one other RF (30/35, 86%); and clinical nerve invasion (31/35, 89%). Immune status influenced ART decision-making (30/35, 86%) with 77% (27/35) more likely to recommend ART for immunosuppressed patients. Consensus was reached to omit ART for pathologic complete response following neoadjuvant immunotherapy (34/35, 97%). Among radiation oncologists, 100% (15/15) agreed the optimal window for ART to the tumor bed is 4-8 weeks and that hypofractionated regimens can be appropriate (12/15, 80%). Consensus was reached for prescription doses of 60-66 Gy in 2 Gy/fx (15/15, 100%) or 50-55 Gy in 2.5 Gy/fx (13/15, 87%), and that superficial radiation and brachytherapy are inappropriate ART modalities for node-negative high-stage CSCC (14/15, 93%). There was no consensus on elective nodal basin irradiation. CONCLUSIONS: This Delphi study provides an expert consensus-based framework to standardize ART for node-negative high-stage CSCC following surgery, informing future guidelines and utilization.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Stevens JS, Barker CA, Bakst RL, et al. US-based Delphi Consensus Study on Adjuvant Radiation Therapy (ART) in Node-Negative Cutaneous Squamous Cell Carcinoma (CSCC). Int J Radiat Oncol Biol Phys. 2026. PMID: 42887677. doi:10.1016/j.ijrobp.2026.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。